![Ronald Stafford Watts](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ronald Stafford Watts
Direktor/Vorstandsmitglied bei Wenkart Foundation
Aktive Positionen von Ronald Stafford Watts
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Wenkart Foundation | Direktor/Vorstandsmitglied | - | - |
Biosceptre International Ltd.
![]() Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Ronald Stafford Watts
Ehemalige bekannte Positionen von Ronald Stafford Watts
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ENERGY ACTION LIMITED | Direktor/Vorstandsmitglied | 12.11.2015 | 30.06.2017 |
Vorsitzender | 14.10.2011 | 12.11.2015 | |
Biosceptre (Aust) Pty Ltd.
![]() Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia. | Direktor/Vorstandsmitglied | - | - |
Ausbildung von Ronald Stafford Watts
The University of New South Wales | Undergraduate Degree |
University of Cambridge | Doctorate Degree |
Statistik
International
Australien | 5 |
Vereinigtes Königreich | 3 |
Operativ
Director/Board Member | 4 |
Chairman | 1 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ENERGY ACTION LIMITED | Commercial Services |
Private Unternehmen | 3 |
---|---|
Biosceptre (Aust) Pty Ltd.
![]() Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia. | Health Technology |
Wenkart Foundation | |
Biosceptre International Ltd.
![]() Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | Health Technology |
- Börse
- Insiders
- Ronald Stafford Watts
- Erfahrung